Tag:
Eliquis
Latest Headlines
Latest Headlines
EMA supports Pradaxa but seeks sharper warnings for bleeding
European regulators say the upside of blockbuster drug Pradaxa still outweighs its the risks of fatal bleeding, but they want some more labeling caveats for the blockbuster drug.
FDA review backs Xarelto for big new use in ACS patients
The anticoagulant won a thumbs-up from FDA reviewers ahead of Wednesday's advisory panel meeting, where FDA experts will weigh a lucrative new indication.
Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib
Next week FDA advisers will take their turn dissecting the upsides and downsides of the first-in-class drug for rheumatoid arthritis.
Pfizer turns to late-stage pipeline to make up for Lipitor crash
The pharma giant is staying focused on the fate of a trio of late-stage therapies that are desperately needed to fill a growing gap.
Bristol turns to blockbuster pipeline as Plavix goes generic
With clot-buster Plavix facing generic competition, the company is banking on some more wins in its pipeline to replace revenue from declining sales of its top seller.
Bayer gets positive ruling from NICE on Xarelto
NICE has recommended the drug for stroke and embolisms in draft guidance, and final guidance may come in April.
Pfizer, BMS face a delay on FDA's megablockbuster decision on apixaban
Pfizer ( $PFE ) and its partner Bristol-Myers Squibb ( $BMY ) will have to wait before hearing whether the FDA will sign off on marketing approval for apixaban, their blockbuster anti-clotting hopeful.
Pradaxa, Xarelto gain reprieve as FDA delays Eliquis decision
Pfizer ( $PFE ) and Bristol-Myers Squibb ( $BMY ) will have to wait three more months for the FDA's latest word on Eliquis . The anticoagulant drug has some of the strongest data among a new cadre of...
Pfizer, Lilly earnings drop on new generic rivals
Pfizer ( $PFE ) and Eli Lilly ( $LLY ) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earnings
Shrinking Pfizer targeting new round of small, tailor-made buyouts and pacts
Pfizer is thinking small these days. In keeping with the deal-making theme at the J.P. Morgan conference, Pfizer ( $PFE ) CEO Ian Read carefully mapped out the pharma giant's near-term strategy, with
